- Email: [email protected]
Correction to Lancet Oncol 2015; 16: 1289
Corrections
Corrections to multiple conflicts of interest statements In five Articles1–5 and two Comments6,7 published in The Lancet Oncology between 2010 and 2014, the conflicts of interest statements for Chris J L M Meijer should also have included ownership of a small number of shares in Delphi Biosciences, which made a lavage self-sampling device, and declaration of a minority stake in Diassay, which sells a CE-labelled GP5+/6+ PCR test. 1
2
3
4
5
6
7
de Sanjose S, Quint WGV, Alemany L, et al, on behalf of the Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048–56. Kocken M, Helmerhorst TJM, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011; 12: 441–50. Castellsagué X, Díaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol 2011; 12: 1023–31. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78–88. Verhoef VMJ, Bosgraaf RP, van Kemenade FJ, et al. Triage by methylation-marker testing versus cytology in women who test HPVpositive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014; 15: 315–22. Meijer CJLM, Berkhof J, Snijders PJF. A new approach to cervical screening. Lancet Oncol 2011; 12: 612–13. Arbyn M, Walker A, Meijer CJLM. HPV-based cervical-cancer screening in China. Lancet Oncol 2010; 11: 1112.
www.thelancet.com/oncology Vol 16 October 2015
Correction to Lancet Oncol 2015; 16: 1338
Correction to Lancet Oncol 2015; 16: e434
Lin JN, Lin CL, Lin MC, et al. Risk of leukaemia in children infected with enterovirus: a nationwide, retrospective, population-based, Taiwanese-registry, cohort study. Lancet Oncol 2015; 16: 1335–43—In this Article, the title of figure 2 should have been “Kaplan-Meier analysis of cumulative incidence of leukaemia for children with or without enterovirus infection after accounting for death as the competing risk”. The subhazard ratio and 95% CI were included in error, and have been removed. This correction has been made to the online version as of Oct 1, 2015 and the printed version is correct.
Bagcchi S. Genetic mutations and outcomes in myeloma. Lancet Oncol 2015; 16: e434—In this News item, the fourth sentence of the third paragraph should read “Patients with CCND1 mutations had worse 2-year overall survival than those without (38·1% [95% CI 14–100] vs 80% [76–84]; p=0·005); similar outcomes were noted with alterations in the DNA repair pathways (TP53, ATM, ATR, and ZNFHX4 mutations)”. This correction has been made as of Oct 1, 2015.
Correction to Lancet Oncol 2015; 16: 1289 Lokody, I. International Liver Cancer Association Annual Conference. Lancet Oncol 2015; 16: 1289—In this News feature, the fourth sentence in the fourth paragraph on Liver transplants for patients with high risk HCC has been changed to read: “Of these, 17 had a liver transplant. The 5-year survival of these patients was superior to those high risk patients that did not have a liver transplant (82% vs 38%; p=0·033).” This correction has been made to the online version as of Oct 1, 2015 and the printed version is correct.
e480
Corrections to multiple conflicts of interest statements In five Articles1–5 and two Comments6,7 published in The Lancet Oncology between 2010 and 2014, the conflicts of interest statements for Chris J L M Meijer should also have included ownership of a small number of shares in Delphi Biosciences, which made a lavage self-sampling device, and declaration of a minority stake in Diassay, which sells a CE-labelled GP5+/6+ PCR test. 1
2
3
4
5
6
7
de Sanjose S, Quint WGV, Alemany L, et al, on behalf of the Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048–56. Kocken M, Helmerhorst TJM, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011; 12: 441–50. Castellsagué X, Díaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol 2011; 12: 1023–31. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78–88. Verhoef VMJ, Bosgraaf RP, van Kemenade FJ, et al. Triage by methylation-marker testing versus cytology in women who test HPVpositive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014; 15: 315–22. Meijer CJLM, Berkhof J, Snijders PJF. A new approach to cervical screening. Lancet Oncol 2011; 12: 612–13. Arbyn M, Walker A, Meijer CJLM. HPV-based cervical-cancer screening in China. Lancet Oncol 2010; 11: 1112.
www.thelancet.com/oncology Vol 16 October 2015
Correction to Lancet Oncol 2015; 16: 1338
Correction to Lancet Oncol 2015; 16: e434
Lin JN, Lin CL, Lin MC, et al. Risk of leukaemia in children infected with enterovirus: a nationwide, retrospective, population-based, Taiwanese-registry, cohort study. Lancet Oncol 2015; 16: 1335–43—In this Article, the title of figure 2 should have been “Kaplan-Meier analysis of cumulative incidence of leukaemia for children with or without enterovirus infection after accounting for death as the competing risk”. The subhazard ratio and 95% CI were included in error, and have been removed. This correction has been made to the online version as of Oct 1, 2015 and the printed version is correct.
Bagcchi S. Genetic mutations and outcomes in myeloma. Lancet Oncol 2015; 16: e434—In this News item, the fourth sentence of the third paragraph should read “Patients with CCND1 mutations had worse 2-year overall survival than those without (38·1% [95% CI 14–100] vs 80% [76–84]; p=0·005); similar outcomes were noted with alterations in the DNA repair pathways (TP53, ATM, ATR, and ZNFHX4 mutations)”. This correction has been made as of Oct 1, 2015.
Correction to Lancet Oncol 2015; 16: 1289 Lokody, I. International Liver Cancer Association Annual Conference. Lancet Oncol 2015; 16: 1289—In this News feature, the fourth sentence in the fourth paragraph on Liver transplants for patients with high risk HCC has been changed to read: “Of these, 17 had a liver transplant. The 5-year survival of these patients was superior to those high risk patients that did not have a liver transplant (82% vs 38%; p=0·033).” This correction has been made to the online version as of Oct 1, 2015 and the printed version is correct.
e480